Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 46.68 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 57.58 | Oscillator | Neutral |
| Williams %R (14) | -50.00 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.04 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 21.73 (+DI 14.9 / -DI 16.7) | Trend | Sell |
Current price $1.83
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| EMA 20 | 1.85 | MA | Sell |
| SMA 20 | 1.84 | MA | Sell |
| EMA 50 | 1.89 | MA | Strong Sell |
| SMA 50 | 2.03 | MA | Strong Sell |
| SMA 200 | 1.64 | MA | Strong Buy |
| Apr 30, 26 |
| D. Boral Capital |
| maintain |
| Buy |
| Buy |
| Mar 5, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Mar 5, 26 | D. Boral Capital | maintain | Buy | Buy |
| Feb 20, 26 | D. Boral Capital | maintain | Buy | Buy |
| Nov 13, 25 | D. Boral Capital | maintain | Buy | Buy |
| Oct 28, 25 | Lake Street | maintain | Buy | Buy |
| Oct 28, 25 | D. Boral Capital | maintain | Buy | Buy |
| Sep 8, 25 | D. Boral Capital | maintain | Buy | Buy |
| Aug 1, 25 | Wells Fargo | maintain | Equal Weight | Equal Weight |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 1, 26 | French Glendon E. Iii | director, officer: President and CEO | S-Sale | 4,098 @ $2.26 | $9.26K |
| Sep 1, 26 | French Glendon E. Iii | director, officer: President and CEO | S-Sale | 37,784 @ $2.26 | $85.39K |
| Sep 1, 26 | Radhakrishnan Srikanth | officer: Chief Science & Techn. Officer | S-Sale | 2,643 @ $2.26 | $5.97K |
| Sep 1, 26 | Radhakrishnan Srikanth | officer: Chief Science & Techn. Officer | S-Sale | 2,121 @ $2.26 | $4.79K |
| Sep 1, 26 | Radhakrishnan Srikanth | officer: Chief Science & Techn. Officer | S-Sale | 3,618 @ $2.26 | $8.18K |
| Sep 1, 26 | Radhakrishnan Srikanth | officer: Chief Science & Techn. Officer | S-Sale | 5,863 @ $2.26 | $13.25K |
| Sep 1, 26 | Lehman David Aaron | officer: General Counsel | S-Sale | 3,807 @ $2.26 | $8.60K |
| Sep 1, 26 | Lehman David Aaron | officer: General Counsel | S-Sale | 2,224 @ $2.26 | $5.03K |
Stock news · updated daily
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, October 27, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Pulmonx (NASDAQ: LUNG - Get Free Report) and Owlet (NYSE: OWLT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Institutional and Insider Ownership 91.0% of Pulmonx shares are
Deutsche Bank AG purchased a new stake in Pulmonx Corporation (NASDAQ: LUNG) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 402,316 shares of the company's stock, valued at approximately $523,000. Deutsche Bank AG owned approximately 0.94% of
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | -0.28 | -0.24 | Beat 14.3% | $22.76M |
| Apr 29, 2026 | -0.33 | -0.33 | Beat 0.0% | $20.59M |
| Mar 4, 2026 | -0.39 | -0.25 | Beat 35.9% | $22.60M |
| Nov 12, 2025 | -0.40 | -0.34 | Beat 15.0% | $21.50M |
| Jul 30, 2025 | -0.40 | -0.38 | Beat 5.0% | $23.86M |
| Apr 30, 2025 | -0.37 | -0.36 | Beat 2.7% | $22.54M |
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | LUNG | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.6x | -8.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.8x | EPS est. -1.02 | In line |
| Price / Book | 2.0x | 3.4x | Discount |
| Price / Sales | 0.9x | 8.2x | Discount |
| EV / EBITDA | -1.8x | -8.2x | Discount |
| Return on equity | -96.7% | — | Weak |
| Gross margin | 77.1% | 74.0% | In line |
| Debt / Equity | 1.43 | 0.47 | Moderate |
| Piotroski / Altman Z | 3/9 | Z -5.82 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 3, 2026 | 2026-09-03 18:23:50 | View |
| 4 | Sep 3, 2026 | 2026-09-03 18:21:58 | View |
| 4 | Sep 3, 2026 | 2026-09-03 18:19:17 | View |
| 4 | Sep 3, 2026 | 2026-09-03 18:17:28 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 17:28:01 | View |
| 10-Q | Aug 4, 2026 | 2026-08-04 16:46:06 | View |
| 8-K | Jul 29, 2026 | 2026-07-29 16:07:39 | View |
| SC 13G/A | Jul 29, 2026 | 2026-07-29 15:19:56 | View |
| 4 | Jun 9, 2026 | 2026-06-09 18:02:42 | View |
| 4 | Jun 9, 2026 | 2026-06-09 18:01:10 | View |
Proxy statement (DEF 14A) disclosures